cover of episode Jia Tolentino on the Ozempic Weight-Loss Craze

Jia Tolentino on the Ozempic Weight-Loss Craze

2023/3/24
logo of podcast The New Yorker Radio Hour

The New Yorker Radio Hour

Chapters

Ozempic, a GLP-1 agonist, was initially approved for type 2 diabetes and obesity treatment. It works by mimicking a hormone that promotes satiation, leading to weight loss. The drug has gained popularity due to celebrity usage and its effectiveness in rapid weight reduction.

Shownotes Transcript

The prescription drug Ozempic was designed to help people with Type 2 diabetes manage their disease, and, under the name Wegovy, to treat obesity. But it has been embraced recently as a tool for weight loss, and many celebrities are rumored to use it in order to shed pounds. Known generically as semaglutide, the drug gives users the feeling of satiation—even to the point of uncomfortable fullness. “One doctor I spoke to compared it to a turkey dinner in a pen,” the staff writer Jia Tolentino tells David Remnick. Tolentino recently reported on) the use and misuse of the drug, and what its prominence among celebrities says about our relationship to thinness today. After some years in which body culture seemed to become more accepting, Tolentino fears the drug will wind the clock back to the brutal insistence on thinness of decades past. “Like any technology, it’s very complicated,” she says. “For some people, this drug might save their lives. For others, it does not make sense to be used in any casual way.”